Compares two lymph node checks in early womb lining cancer
Tests sentinel lymph node mapping against full lymph node removal in endometrial cancer.
Plain-language title generated from the registry record
Registry title: Randomized Comparison Between Sentinel Lymph Node Biopsy and Lymph Node Dissection in Early Stage Endometrial Cancer
Key facts
- Where
- Seoul, South KoreaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 20 to 80 with endometrial cancer that has not been treated and is thought to be at an early stage (stage I-II). It compares two ways of checking the lymph nodes during surgery.
- Age
- 20 to 80 years
- Sex
- Women only
- Disease stage
- Endometrial cancer that has never been treated, thought to be FIGO stage I-II, FIGO grade 1, 2 or 3. Several tumour types are allowed, such as endometrioid, serous and clear cell.
- Earlier treatment
- No earlier treatment for this cancer. No earlier lymph node removal in the pelvis or around the aorta. No earlier radiation or chemotherapy to the belly or pelvis.
Main reasons for not taking part
- Thought to be FIGO stage III-IV
- Neuroendocrine tumour type
- Swelling (lymphedema) of the leg or groin
- Allergy to indocyanine green
- Pregnant or breast-feeding
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 80 years old?
Source: NCT04845828, who can take part
Where in South Korea
- Asan Medical CenterSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Asan Medical Center
- Trial code
- NCT04845828
- Record updated
- 21 February 2022
- Original description
Through this clinical trial, the investigators aim to verify the usefulness and stability of sentinel lymph node mapping in endometrial cancer of clinical stage I-II.Read full original descriptionShow less
Prospective Randomized Comparison of Sentinel Lymph Node Mapping Using Indocyanine Green and Conventional Pelvic Lymph Node Dissection in Clinical Stage I-II Endometrial Cancer
Through this clinical trial, the investigators aim to verify the usefulness and stability of sentinel lymph node mapping in endometrial cancer of clinical stage I-II.
Inclusion: 20 ~ 80 years old female; histologically diagnosed endometrial cancer that has never been treated before; histological type :endometrioid, mucinous, serous, clear cell, uindifferentiated, dedifferentiated, mesonephric adenocarcinoma, mesonephric-like adenocarcinoma, carcinosarcoma, and mixed type; histological grade : FIGO grade 1, 2, 3; Presumed FIGO stage I-II; Planed for laparoscopic or robotic hystererctomy and lymph adenectomy; Largest pelvic or para-aortic lymph node diameter = or < 15 mm in short axis on MRI; ECOG performance status 0-2; ASA PS 0-2; WBC ≥ 3,000/mm3, Platelets ≥ 100,000/mm3, Creatinine ≤ 2.0 mg/dL ,Bilirubin ≤ 1.5 x institutional upper limit normal ,SGOT, SGPT, and ALP ≤ 3 x institutional upper limit normal; A patient who voluntarily signed a document for the study.
Exclusion: previous pelvic or paraaortic lymph node dissection; previous radiation or concurrent chemoradiation therapy of abdomen or pelvis; previous chemotherapy due to malignant disease of abdomen or pelvis; Other disease involving lymphatic system; Patients who have had or have been treated for cancer within five years, other than non-melanoma skin cancer, carcinoma in situ of uterine cervix, stomach or bladder; severe, uncontrolled underlying diseases or underlying disease with complications; hypersensitivity to indocyanine green; Presumed FIGO stage III-IV; Neuroendocrine tumor histology; lymphedema of the lower extremity or inguinal area; a pregnant or breast-feeding woman.